SRTD Biotech develops RNA therapies designed to activate selectively inside diseased cells.
Boehringer Ingelheim Venture Fund
Activity from announced rounds
Boehringer Ingelheim Venture Fund is a corporate venture investment operation identified in Cloverleaf Bio and Brainomix financing histories.
Recorded funding activity
Cloverleaf develops engineered transfer-RNA therapies intended to inhibit cancer cells’ RNA-modifying enzymes. Brainomix develops AI imaging tools for stroke and lung fibrosis. The announcements connect the venture operation to both experimental therapeutics and clinical image analysis.
- Rounds participated in
- 3
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $75.1M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in all activityCloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.
Develops AI-powered imaging tools for stroke and lung fibrosis